Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
E126853-5mg | 5mg | In stock | $112.90 | |
E126853-25mg | 25mg | In stock | $399.90 | |
E126853-100mg | 100mg | In stock | $999.90 | |
E126853-500mg | 500mg | In stock | $3,499.90 |
Selective ferrotopsis activator
Synonyms | 2-(1-(4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)ethyl)-3-(2-ethoxyphenyl)quinazolin-4(3H)-one | MFCD09837984 | 2-[1-[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4(3H)-Quinazolinone | 2-(1-(4-(2-(4-Chlorophenoxy)acetyl)-1-pipera |
---|---|
Specifications & Purity | ≥99% |
Biochemical and Physiological Mechanisms | Description:IC50 Value: 0.1 uM (VDAC-2) [1]Erastin is a compound that interacts with VDAC, blocked and reversed mitochondrial depolarization after microtubule destabilizers in intact cells and antagonized tubulin-induced VDAC blockage in planar bilayers.V |
Storage Temp | Store at -20°C,Argon charged |
Shipped In | Ice chest + Ice pads |
Note | Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Erastin is a cell-permeable piperazinyl-quinazolinone. It interacts with antiporter system Xc-. Application: Erastin has been used: |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
IUPAC Name | 2-[1-[4-[2-(4-chlorophenoxy)acetyl]piperazin-1-yl]ethyl]-3-(2-ethoxyphenyl)quinazolin-4-one |
---|---|
INCHI | InChI=1S/C30H31ClN4O4/c1-3-38-27-11-7-6-10-26(27)35-29(32-25-9-5-4-8-24(25)30(35)37)21(2)33-16-18-34(19-17-33)28(36)20-39-23-14-12-22(31)13-15-23/h4-15,21H,3,16-20H2,1-2H3 |
InChi Key | BKQFRNYHFIQEKN-UHFFFAOYSA-N |
Canonical SMILES | CCOC1=CC=CC=C1N2C(=O)C3=CC=CC=C3N=C2C(C)N4CCN(CC4)C(=O)COC5=CC=C(C=C5)Cl |
Isomeric SMILES | CCOC1=CC=CC=C1N2C(=O)C3=CC=CC=C3N=C2C(C)N4CCN(CC4)C(=O)COC5=CC=C(C=C5)Cl |
WGK Germany | 3 |
PubChem CID | 11214940 |
Molecular Weight | 547.04 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
L2205572 | Certificate of Analysis | Sep 12, 2024 | E126853 |
L2205573 | Certificate of Analysis | Sep 12, 2024 | E126853 |
G2430349 | Certificate of Analysis | Jun 21, 2024 | E126853 |
G2430350 | Certificate of Analysis | Jun 21, 2024 | E126853 |
G2430351 | Certificate of Analysis | Jun 21, 2024 | E126853 |
C2426003 | Certificate of Analysis | Aug 10, 2023 | E126853 |
H2328430 | Certificate of Analysis | Aug 10, 2023 | E126853 |
H2328431 | Certificate of Analysis | Aug 10, 2023 | E126853 |
H2328432 | Certificate of Analysis | Aug 10, 2023 | E126853 |
L2205441 | Certificate of Analysis | Nov 22, 2022 | E126853 |
L2205576 | Certificate of Analysis | Nov 22, 2022 | E126853 |
F2209101 | Certificate of Analysis | May 19, 2022 | E126853 |
F2209128 | Certificate of Analysis | May 19, 2022 | E126853 |
F2209175 | Certificate of Analysis | May 19, 2022 | E126853 |
F2209177 | Certificate of Analysis | May 19, 2022 | E126853 |
C2221030 | Certificate of Analysis | Mar 24, 2022 | E126853 |
Solubility | 25°C: DMSO |
---|---|
Sensitivity | air & heat sensitive |
Pictogram(s) | GHS06 |
---|---|
Signal | Danger |
Hazard Statements | H301:Toxic if swallowed |
Precautionary Statements | P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P270:Do not eat, drink or smoke when using this product. P330:Rinse mouth. P301+P316:IF SWALLOWED: Get emergency medical help immediately. |
WGK Germany | 3 |
Starting at $241.90
1. Junwei Liu, Meihong Zhang, Chuanbin Wu, Xin Pan, Zhengwei Huang. (2023) TPGS/soluplus® blended micelles: an effective strategy for improving loading capacity of ferroptosis inducer erastin. JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY, [PMID:] |
2. Qiang-Ming Li, Tong Xu, Xue-Qiang Zha, Xiao-Wen Feng, Feng-Yun Zhang, Jian-Ping Luo. (2024) Buddlejasaponin IVb ameliorates ferroptosis of dopaminergic neuron by suppressing IRP2-mediated iron overload in Parkinson's disease. JOURNAL OF ETHNOPHARMACOLOGY, 319 (23): (117196). [PMID:37717841] |
3. Jiangbo Nie, Yuhang Ling, Mingchao Jin, Zhuo Chen, Wei Liu, Weiyun Shen, Tianshun Fang, Jianyou Li, Ying He. (2023) Butyrate enhances erastin-induced ferroptosis of osteosarcoma cells via regulating ATF3/SLC7A11 pathway. EUROPEAN JOURNAL OF PHARMACOLOGY, (176009). [PMID:37619784] |
4. Xinmei Wang, Shanshan Li, Jiayu Yu, Wenlin Wang, Zhuoqi Du, Shuchun Gao, Yin Ma, Ruixin Tang, Ting Liu, Shiping Ma, Qiang Fu, Xueyang Deng. (2023) Saikosaponin B2 ameliorates depression-induced microglia activation by inhibiting ferroptosis-mediated neuroinflammation and ER stress. JOURNAL OF ETHNOPHARMACOLOGY, 316 (116729). [PMID:37277081] |
5. Xinyu Zhang, Xueli Xu, Huimin Liu, Nengyi Ni, Shuangqing Liu, Yufang Gong, Guiqi Ma, Linlin Song, Qingwei Meng, Qing Fan, Xiao Sun. (2023) CCR2-overexpressing biomimetic carrier-free nanoplatform for enhanced cascade ferroptosis tumor therapy. Acta Biomaterialia, 166 (604). [PMID:37156432] |
6. Huang Hui, Ye Zhifang, Li Zhengzhao, Wang Bo, Li Ke, Zhou Kai, Cao Huiyuan, Zheng Jiaxuan, Wang Guangji. (2023) Employing machine learning using ferroptosis-related genes to construct a prognosis model for patients with osteosarcoma. Frontiers in Genetics, 14 [PMID:36733341] |
7. Jing Zhao, Mingming Ma, Lei Li, Gaoli Fang. (2023) Oxysophoridine protects against cerebral ischemia/reperfusion injury via inhibition of TLR4/p38MAPK‑mediated ferroptosis. Molecular Medicine Reports, 27 (2): (1-11). [PMID:36601753] |
8. Feng-guo Zhai, Qi-chao Liang, Yi-yan Wu, Jia-qi Liu, Jia-wei Liu. (2022) Red ginseng polysaccharide exhibits anticancer activity through GPX4 downregulation-induced ferroptosis. PHARMACEUTICAL BIOLOGY, 60 (1): (909-914). [PMID:35575436] |
1. Torii S et al.. (2016) An essential role for functional lysosomes in ferroptosis of cancer cells.. Biochem J, [PMID:26759376] |
2. Chen L et al.. (2021) Characterization of Interplay Between Autophagy and Ferroptosis and Their Synergistical Roles on Manipulating Immunological Tumor Microenvironment in Squamous Cell Carcinomas.. Front Immunol, 12 (739039). [PMID:35185859] |
3. Xie Y et al.. (2016) Ferroptosis: process and function.. Cell Death Differ, [PMID:26794443] |
4. Simamura E et al.. (2008) Mitochondrial voltage-dependent anion channels (VDACs) as novel pharmacological targets for anti-cancer agents.. J Bioenerg Biomembr, 40 (3): (213-7). [PMID:18704666] |
5. Haß C et al.. (2016) Sensitization of acute lymphoblastic leukemia cells for LCL161-induced cell death by targeting redox homeostasis.. Biochem Pharmacol, [PMID:26774450] |
6. Junwei Liu, Meihong Zhang, Chuanbin Wu, Xin Pan, Zhengwei Huang. (2023) TPGS/soluplus® blended micelles: an effective strategy for improving loading capacity of ferroptosis inducer erastin. JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY, [PMID:] |
7. Qiang-Ming Li, Tong Xu, Xue-Qiang Zha, Xiao-Wen Feng, Feng-Yun Zhang, Jian-Ping Luo. (2024) Buddlejasaponin IVb ameliorates ferroptosis of dopaminergic neuron by suppressing IRP2-mediated iron overload in Parkinson's disease. JOURNAL OF ETHNOPHARMACOLOGY, 319 (23): (117196). [PMID:37717841] |
8. Jiangbo Nie, Yuhang Ling, Mingchao Jin, Zhuo Chen, Wei Liu, Weiyun Shen, Tianshun Fang, Jianyou Li, Ying He. (2023) Butyrate enhances erastin-induced ferroptosis of osteosarcoma cells via regulating ATF3/SLC7A11 pathway. EUROPEAN JOURNAL OF PHARMACOLOGY, (176009). [PMID:37619784] |
9. Xinmei Wang, Shanshan Li, Jiayu Yu, Wenlin Wang, Zhuoqi Du, Shuchun Gao, Yin Ma, Ruixin Tang, Ting Liu, Shiping Ma, Qiang Fu, Xueyang Deng. (2023) Saikosaponin B2 ameliorates depression-induced microglia activation by inhibiting ferroptosis-mediated neuroinflammation and ER stress. JOURNAL OF ETHNOPHARMACOLOGY, 316 (116729). [PMID:37277081] |
10. Xinyu Zhang, Xueli Xu, Huimin Liu, Nengyi Ni, Shuangqing Liu, Yufang Gong, Guiqi Ma, Linlin Song, Qingwei Meng, Qing Fan, Xiao Sun. (2023) CCR2-overexpressing biomimetic carrier-free nanoplatform for enhanced cascade ferroptosis tumor therapy. Acta Biomaterialia, 166 (604). [PMID:37156432] |
11. Huang Hui, Ye Zhifang, Li Zhengzhao, Wang Bo, Li Ke, Zhou Kai, Cao Huiyuan, Zheng Jiaxuan, Wang Guangji. (2023) Employing machine learning using ferroptosis-related genes to construct a prognosis model for patients with osteosarcoma. Frontiers in Genetics, 14 [PMID:36733341] |
12. Jing Zhao, Mingming Ma, Lei Li, Gaoli Fang. (2023) Oxysophoridine protects against cerebral ischemia/reperfusion injury via inhibition of TLR4/p38MAPK‑mediated ferroptosis. Molecular Medicine Reports, 27 (2): (1-11). [PMID:36601753] |
13. Feng-guo Zhai, Qi-chao Liang, Yi-yan Wu, Jia-qi Liu, Jia-wei Liu. (2022) Red ginseng polysaccharide exhibits anticancer activity through GPX4 downregulation-induced ferroptosis. PHARMACEUTICAL BIOLOGY, 60 (1): (909-914). [PMID:35575436] |